Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Epirubicin in Metastatic Breast Cancer
NCT02392845Phase 1Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Jun 2005
- Primary completion
- Mar 2009
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of docetaxel and epirubicin in breast cancer, sponsored by Hospices Civils de Lyon. Primary endpoint: Dose-limiting Toxicities at 84 days. Started Jun 2005; status: completed.
02
Drugs
docetaxelepirubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02392845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02392845.